Practical Management of Thyroid Cancer: A Multidisciplinary Approach

ISBN-13: 9783031386046 / Angielski

Ujjal K. Mallick; Clive Harmer

Spis treści

 

 

Foreword — Professor J Shah

Head and Neck and Thyroid Surgical Service, Memorial Sloan Kettering Cancer Centre, New York, USA

 

Introduction

1.Global Unity, Scientific Progress and advances in thyroid cancer management beyond the Pandemic, Ujjal K. Mallick and Clive Harmer

 

NEW SECTION: SPECIAL SECTION-Lessons Learnt

2. Covid-Sars- 2 Pandemic, the impact on management of thyroid cancer

[Experience from different countries—- One long chapter with 1/2 page sections from different countries, similar to implementation of guidelines in 2nd edition by Pitoia /Mallick?]

Introduction — UK Mallick (UK), G Randolph (Boston), Clive Harmer

A) Thyroid cancer and Telemedicine During the COVID-19 Pandemic

Sumedha V Chablani, Mona M Sabra Weil Cornell, MSKCC New York

 svc9004@nyp.org 

 

b) Thyroid cancer in the age of COVID-19.

Tsang VHM, Gild M, Glover A, Clifton-Bligh R, Robinson BG

venessa.tsang@sydney.edu.au.   Australia 

 

c) Thyroid surgery during coronavirus-19 pandemic phases I, II and III: lessons learned in China, South Korea, Iran and Italy

H. Sun, P. Del Rio, J. Jafari, H. Y. Kim, et al

s_h@jlu.edu.cn; paolo.delrio@unipr.it; hoonyubkim@korea.ac.kr et al.

 

 

d) Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challenge. Italy and France

Michele Klain,  Martin Schlumberger, Alberto Cuocolo  et al

 

e). Thyroid cancer surgery during Covid-19 UK

Vin Paleri, Royal Marsden, London, et al

f). Thyroid cancer surgery  during Covid-19 -Principles

AR Shaha, MSKCC New York

g). Patients’ Perspective, Covid -19 and Thyroid cancer  

Kate Farnell, R Bliss, P Perros, S Jhonson, N Armstrong,

h) Running a National Clinical Trial during the Pandemic

UK Mallick, J Wadsley, A Hackshaw

 

NEW SECTION Machine Learning and Artificial Intelligence

New Chapter

3. Impact of Artificial Intelligence in the field of Thyroid cancer

Fabiano Bini,,Pierpaolo Trimboli et al.

Department of Mechanical and Aerospace Engineering, Sapienza-University of Rome, 00184 Rome, Italy;

Servizio di Endocrinologia e Diabetologia, Ospedale Regionale di Lugano e Mendrisio, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland & Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), 6900 Lugano, Switzerland

fabiano.bini@uniroma1.it, pierpaolo.Trimboli@eoc.ch.

 

4.Risk Stratifying Indeterminate Thyroid Nodules with Machine Learning.

Luong G, Idarraga AJ, Hsiao V, Schneider DF 

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin  Wisconsin. USA

  schneiderd@surgery.wisc.edu

 

NEW

5. Artificial Intelligence for Personalized Medicine in thyroid cancer : Current Status and Future Perspectives

Ling-Rui Li,  Bo Du, , Han-Qing Liu,  and Chuang Chen , *

 

 Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China,

School of Computer Science, Wuhan University, Wuhan, China,

Institute of Artificial Intelligence, Wuhan University, Wuhan, China,

Edited by: Randy Yeh, Memorial Sloan Kettering Cancer Center, United States

Reviewed by: Vasyl Vasko, Uniformed Services University of the Health Sciences, United States; Barbara Maria Jarzab, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland; Alessandro Antonelli, University of Pisa, Italy

*Correspondence: Chuang Chen, moc.361@9642cnehc

 

THE ENVIRONMENT AND THYROID CANCER

New Chapter

6.Global rise in the incidence of thyroid cancer , geographic  and environmental influences .

Roman SA. et al

Department of Surgery, University of California, San Francisco, USA. Electronic address: sanziana.roman@ucsf.edu.

 

RESERVE

New Chapter

7. Ambient particulate matter air pollution and increased risk of papillary thyroid cancer

Shkala Karzai, Zhenyu Zhang, Aarti Mathur 

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.     
Department of Global Health, Peking University School of Public Health, Beijing, China.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Otolaryngology-Head a
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: amathu10@jhmi.edu.

 

Part I Multidisciplinary Approach to Management of Thyroid cancer  

 The UK Evidence-Based Guidelines for the Management
of Thyroid cancer : Key Recommendations .  DELETE

The  American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid
Nodules and Differentiated Thyroid cancer : Key Recommendations-  DELETE   B Haugen et al

NEW

8. Challenges of thyroid cancer Guideline development and implementation

B Haugen, A Sawka et al.

 

9. The ESMO Guidelines for thyroid cancer (Latest Edition). Kate Newbold et al Consultant Oncologist, Royal Marsden Hospital et al

 

NEW

10. NCCN Guidelines (Latest version) Cord Sturgeon et al, North Western University ,Chicago

NEW

11.African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings.

Fagan JJ, Randolph GW (Boston USA)  et al

Department of Otohinolaryngology, University of Cape Town, Cape Town, South Africa.  johannes.fagan@uct.ac.za

 

NEW

12.Latin American guidelines and adaptation of ATA Guidelines  in  other Low and Middle Income Countries   Fabián Pitoia, Anil D’cruz (India),  Ujjal K. Mallick

 

NEW

13. Disparities in Thyroid cancer  Care. HAYMART M et al.     meganhay@med.umich.edu

Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building 16, Room 408E, Ann Arbor, MI 48109, USA

 

Part II The Diagnosis of Thyroid cancer  

14. Ultrasonography in Diagnosis and Management of Thyroid cancer: Current International Recommendations Significant Updating  with Artificial Intelligence TIRADS

  Dong Gyu Na, Ji-hoon Kim, and Eun Ju Ha

 

 

15. Molecular Diagnosis of Thyroid Nodules. Significant Updating. David N. Poller et al,

 

 

NEW CHAPTER

 

16. Current Diagnostic and Theranostic Approaches in the Management

of Thyroid cancer -An inter societal joint statement

Elisei R ,Seza A. Gulec, Sukhjeet Ahuja et al.

Rossella.elisei@med.unipi.it

 

.LIQUID BIOPSY

New Chapter  . . . . . . . .

17. Liquid Biopsy - Flow Cytometry  and Circulating Tumour Cells in Thyroid cancer . -. D Jamieson (Newcastle Univ) U K Mallick, et al

 

NEW

18.Liquid Biopsy in Thyroid cancer  -Opportunities and Challenges

Romano C, Martorana F, Pennisi MS, Stella S, Massimino M, Tirrò E, Vitale SR, Di Gregorio S, Puma A, Tomarchio C, Manzella L.

manzella@unict.it 

 

 

NEW

 

[RESERVE LIST

INDIA

. Plasma Cell-Free DNA to Differentiate Malignant from Benign Thyroid Nodules and Thyroseq V 3, Afirma GEC.

Susmita Dutta, Soham Tarafdar, Sujoy Ghosh.  et al

drsujoyghosh2000@gmail.com]

 

Part III Initial Thyroid Surgery

  The 21st Century Endocrine Surgeon, Nadine R. Caron, Tracy S. Wang, Cord Sturgeon,
and Orlo H. Clark ————DELETE

 

Initial  Thyroid Surgery  -Lobectomy vs Total Thyroidectomy

 Dae Kim et al

19.Change in title and author.

Management of the Neck in Well-Differentiated Thyroid cancer  ( Ashok R Shaha   MSKCC  New York  et al shahaa@mskcc.org 

 

20 Advances in Thyroid Surgery. UPDATE. Recent Developments,  Sara L. Richer, Dipti Kamani, and Gregory W. Randolph

 

 

 

Part IV Management of Low Risk Differentiated Thyroid cancer  

21. Risk Stratification and Current Management of Low
Risk Thyroid cancer . (UPDATE), Sana A. Ghaznavi and R. Michael Tuttle  US EXPERIENCE

NEW CHAPTER

22.Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015

Prof Barbara Jarzab ( Poland) et al  bjarzab@io.gliwice.pl.

23.  Management of Low-Risk Papillary Thyroid Carcinoma
and Papillary Microcarcinoma: The Japanese
Experience . . . . .Update  Yasuhiro Ito and Akira Miyauchi

NEW CHAPTER

24 Is Less More?  for Low-Risk Differentiated Thyroid cancer and Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment

Lubitz CC, Sosa JA,  et al      clubitz@mgh.harvard.edu

 

NEW CHAPTER

China

25..Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma: A Propensity-Matched Cohort Study of 884 Patients

                Lin Yan, Mingbo Zhang, Qing Song, and Yukun Luo

                Address correspondence to: Yukun Luo, MD, Department of Ultrasound, The First Medical Centre, Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing 100853, China

E-mail Address: lyk301@163.com

26. Differentiated Thyroid cancer: A Health Economic Review.

Tolley NS, Di Marco AN, Palazzo FF.et al

 

27.  Radioiodine Ablation:. UPDATE

Furio Pacini and Maria Grazia Castagna

 

CHANGE TITLE &UPDATE

28. Intersocietal  Consensus in the Use of (131)I Therapy in Differentiated Thyroid cancer : - The Martinique Principles and  current Dosimetric Approaches:. . . . . . . . . . . .

Michael Lassmann, Markus Luster,
and Heribert Hänscheid

29.External Radiation in Differentiated Thyroid cancer
IMRT,Stereotactic Radiotherapy and beyond . .UPDATE . . . . . . . . . . James D. Brierley and Meredith E. Giuliani

Part V Follow Up and Longterm Management of Differentiated Thyroid cancer  

Thyroglobulin . . . . . . . . DELETE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 Shireen Fatemi and Carole Spencer

 

 Management of Post-operative Hypocalcemia . . DELETE. . . . . . . . . . Claudio Marcocci

30.. Radioiodine Refractory Thyroid cancer  . . MAJOR . UPDATE. . . . . . . . . . . . . . . Amandine Berdelou, Sophie Leboulleux,
and Martin Schlumberger

 

Part VI
31. A Multidisciplinary Approach-Medullary Thyroid cancer  . . .  UPDATE —

 

Wells S A, et al. Genetics BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA   wellss@mail.nih.gov.

.  Medullary Thyroid cancer : Diagnosis
and Non Surgical. Management .. . . .. .DELETE . . . . . . . . . . . . . . . .

. Rossella Elisei and Antonio Matrone

 

RESERVE LIST

NEW CHAPTER

 

[.Parathyroid cancer : An update

Juan P Rodrigo  Carlos Suárez  Antti A Mäkitie, Ashok R

Shaha , Alfio Ferlito  jprodrigo@uniovi.es.]

 

NEW

32. . Diagnosis and management of primary mesenchymal tumours of the thyroid gland.

Kebebew E, Klubo-Gwiezdzinska J. Et al  kebebew@stanford.edu

 

 

 

 Familial Non-Medullary Thyroid cancer . . . .DELETE . . . . . . . . . . . . 241 Joanna Klubo-Gwiezdzinska, Yevgenia Kushchayeva,
Sudheer Kumar Gara, and Electron Kebebew

 

RESERVE LIST

NEW

. Thyroid cancer  under the scope of emerging technologies.

Tarabichi M, Demetter P, Craciun L, Maenhaut C, Detours V.

 

Reserve List

. Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine

Antonio Ieni,1, and Giovanni Tuccari1 et al.  aieni@unime.it  tuccari@unime.it

 

Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, Section of Pathology, University of Messina, 98125 Messina, Italy; ti.eminu@iraccut

2Department of Clinical and Experimental Medicine, University of Messina, Viale Gazzi, 98125 Messina, Italy; ti.eminu@ativ.otrebor (R.V.); ti.eminu@agnevnebs (S.B.]

 

Part VII Thyroid cancer  in Children

33.. Pediatric Differentiated Thyroid Carcinoma ..MAJOR UPDATE  including NTRK Fusion and Tumour Agnostic drugs. Steven G. Waguespack and Jonathan D. Wasserman

Part VIII Aggressive Thyroid cancer s

34. Anaplastic Thyroid cancer  . . . American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid cancer .

Bible KC, E,,Smallridge R, et al.  bible.keith@mayo.edu 

 

NEW CHAPTER

39..    Thyroid cancer s: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

Rossella Elisei ,Loredana Lorusso,Eleonora Molinaro, Pisa Italy

 

 Palliative Care and Quality of Life Update. Mary Comiskey —-DELETE

Part IX Future Developments and Directions for Research in Thyroid cancer  

40.Genomics Driven Trials
in Thyroid cancer. MAJOR UPDATE. Maria E. Cabanillas, et al,

41.   Thyroid cancer  -NEW Trial designs  and Interpretation of  trial  results  for the Health care professional . .MAJOR . RECENT ADVANCES, PLATFORM TRIALS TUMOUR AGNOSTIC  .DRUG development. . . . . . . . . . . . . . . . . . . . . . . . . . . Allan Hackshaw et al

 The Barriers to Uniform Implementation of Clinical
Practice Guidelines (CPG) for Thyroid cancer . . . . . . . . . . . . . Ujjal K. Mallick and Fabián Pitoia —-DELETE

 

42.   Quality of Life and Survivorship:. . . Katherine Kendell and Nicola Jane Armstrong   UPDATE

 

O autorze

Dr Ujjal Mallick, MBBS MS FRCPE (Hon) FRCP (Hon) FRCR Consultant Clinical Oncologist Formerly Consultant Oncologist and  past Chair, Multidisciplinary thyroid cancer team (MDT), Freeman Hospital, Newcastle upon Tyne, UK, a centre of excellence for thyroid cancer. Chief Investigator of the first UK National Thyroid Cancer Trial -Hilo-( NEJM 2012) which helped modify international guidelines and practice and of the on-going second UK trial-IoN. One of the lead authors of the first UK National guideline. The MDT obtained many prestigious national awards including–Best NHS "Hospital Doctor" Oncology Team of the Year” Award 2007, Best Thyroid cancer MDT in NHS Peer Review 2011, first prize in NHS innovations award 2007 and others. He initiated an acclaimed MD clinic involving an expert thyroid cancer patient. Current interests are trials, biomarkers and guideline implementation. 

Dr Clive Harmer MB FRCR FRCP. Clinical Oncologist Consultant in Clinical Oncology at St. George’s Healthcare NHS Trust and The Royal Marsden NHS Trust (where he was head of the Thyroid unit) until August 2005. Recognized teacher of the University of London and Honorary Senior Lecturer at the Institute of Cancer Research.

Blurb

Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.

It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.

The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.

The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.

This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.